Floatz Rating
BB71/100
Confidence
Indicative
Sponsor
Alar Pharmaceuticals Inc.
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
75High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06965569CT.gov Multiple Ascending Dose Phase 1 Study of ALA-3000 | — | Completed | — | — | — |
NCT06842992CT.gov A Phase II Study to Evaluate NH102 for Depression | — | Completed | — | — | — |
NCT07253207CT.gov Efficacy and Safety Study of Levomilnacipran Hydrochloride Extended-Release Capsules in Major Depressive Disorder | — | Completed | — | — | — |
NCT06278779CT.gov Comparative Effectiveness Study of Two Forms of Ketamine for Treatment-resistant Depression | — | Recruiting | — | — | — |
NCT05930912CT.gov Psychiatric Orders in Psychoanalytic Treatment of ASD | — | Unknown | — | — | — |
NCT04446039CT.gov Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea | — | Completed | — | — | — |
NCT05018013CT.gov Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression | — | Unknown | — | — | — |
NCT04847245CT.gov Esketamine Adjuvant Therapy for Patients With Chronic Visceral Pain Comorbid Major Depressive Disorder | — | Unknown | — | — | — |
NCT04697693CT.gov Antidepressant Response in Older Adults With Comorbid PTSD and MDD | — | Terminated | — | — | — |
NCT04476030CT.gov A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder | — | Completed | — | — | — |
Show 31 more trialsShow fewer
NCT03623711CT.gov A Prediction Study of Multiple Indexes of the Effect of Different Mechanisms of Antidepressants Treatment on Depression | — | Unknown | — | — | — |
NCT02869035CT.gov Treatment Outcome in Major Depressive Disorder | — | Completed | — | — | — |
NCT02497287CT.gov A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression | — | Completed | — | — | — |
NCT02417064CT.gov A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression | — | Completed | — | — | — |
NCT02418585CT.gov A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression | — | Completed | — | — | — |
NCT02711215CT.gov Patient Stratification and Treatment Response Prediction in Neuropharmacotherapy Using Hybrid Positron Emmission Tomography/Magnetic Resconance Imaging (PET/MR) | — | Unknown | — | — | — |
NCT05267873CT.gov Combining Data Sources to Identify Effect Moderation for Personalized Mental Health | — | Completed | — | — | — |
NCT01896349CT.gov Interpersonal Psychotherapy for Treatment Resistant Depression | — | Unknown | — | — | — |
NCT01764867CT.gov Algorithm Guided Treatment Strategies for Major Depressive Disorder | — | Unknown | — | — | — |
NCT01564862CT.gov Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder | — | Completed | — | — | — |
NCT01436162CT.gov Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder | — | Completed | — | — | — |
NCT01360866CT.gov Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial) | — | Completed | — | — | — |
NCT01435759CT.gov SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder | — | Completed | — | — | — |
NCT01288079CT.gov A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder. | — | Terminated | — | — | — |
NCT01153009CT.gov Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder | — | Completed | — | — | — |
NCT01145755CT.gov 6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder | — | Terminated | — | — | — |
NCT01140906CT.gov Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 15 and 20 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults | — | Completed | — | — | — |
NCT01369290CT.gov Electroencephalography (EEG) Signal Processing | — | Unknown | — | — | — |
NCT00905424CT.gov Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant | — | Completed | — | — | — |
NCT00854100CT.gov Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder | — | Completed | — | — | — |
NCT00844194CT.gov Duloxetine in Patients With Diabetic in Peripheral Neuropathic Pain With or Without Co-morbid Major Depressive Disorder | — | Completed | — | — | — |
NCT00811252CT.gov Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 5 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Elderly Patients | — | Completed | — | — | — |
NCT00810069CT.gov Early Versus Delayed Switch in Medication in Patients With Major Depressive Disorder | — | Completed | — | — | — |
NCT00672620CT.gov Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder | — | Completed | — | — | — |
NCT00635219CT.gov Randomised Placebo-controlled Duloxetine-referenced Efficacy and Safety Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder | — | Completed | — | — | — |
NCT00599911CT.gov Dose-finding Study With Lu AA24530 in Major Depressive Disorder | — | Completed | — | — | — |
NCT00414323CT.gov Evaluation of the Effects of Duloxetine on Norepinephrine | — | Completed | — | — | — |
NCT00366652CT.gov Study Evaluating the Effects of DVS SR and Duloxetine on the Pharmacokinetics of Desipramine in Healthy Subjects | — | Completed | — | — | — |
NCT00384033CT.gov Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder | — | Completed | — | — | — |
NCT00351910CT.gov Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder | — | Completed | — | — | — |
NCT01148472CT.gov Efficacy and Tolerability of Escitalopram and Duloxetine in Outpatients With Major Depressive Disorder | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Major Depressive Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Duloxetine (this asset) | Alar Pharmaceuticals Inc. | Approved | BB · 71 |
| Risperidone | Johns Hopkins University | P4 | BBB |
| Selegiline | Corium Innovations, Inc. | P4 | BBB |
| Edivoxetine | Eli Lilly and Company | P3 | BBB |
| Brexpiprazole | Nova Scotia Health Authority | P4 | BBB |
| (1S,2R)-MILNACIPRAN | Allergan | P4 | BBB |
| Vortioxetine | Mayo Clinic | P4 | BBB |
| Amitriptyline | e-Therapeutics PLC | P4 | BBB |
| Citalopram | Xinyu Zhou | P4 | BBB |
+42 more in the Major Depressive Disorder cohort
Other indications for Duloxetine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Diabetic Neuropathy | — | P4 | A · 81 |
| Fibromyalgia | — | P4 | BBB · 74 |
| Osteoarthritis | — | P4 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Duloxetine in Major Depressive Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/duloxetine-major-depressive-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →